NBCA/X
May 8, 2026, 06:03
Risk-Stratified HRT Use Following VTE – NBCA
NBCA shared a post on X:
“The blanket ‘no HRT after VTE’ approach is being challenged — and Dr. Cromwell is leading that conversation.
Her focus: which patient, which formulation, which risk level.
Route matters — transdermal > oral.
Thrombophilia and provocation status are critical.
Progestogen choice matters.
Hematology plus gynecology must collaborate.
Join Dr. Cromwell at NBCA’s May PEP Talk: Women and Blood Clots.
May 12 | 7 PM ET.”
Stay updated with Hemostasis Today.
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: Don’t Let EDTA Fool You – When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation
-
Jun 23, 2026, 19:20Simos Kokkovos: 1st Ever Mobile Stroke Unit in Greece is on its way to Metropolitan Hospital
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association